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Difficult ethical and regulatory challenges are raised whenever children are 
enrolled in non-beneficial research.  Their resolution takes on new significance 
in the light of transnational pharmaceutical development trials in developing 
countries.  This paper examines what international guidelines exist and how 
they address the challenges posed by involving children in non-beneficial 
clinical trials, focussing on the concept of ‘minimal’ risk as a legal and ethical 
standard to protect children from exposure to unwarranted risks presented by 
such trials.  It reviews approaches to the question of minimal risk before 
evaluating the adequacy of existing international guidelines to address the needs 
of children and what can be done to strengthen them. 
I.  Introduction 
The cornerstone of research ethics involving human subjects in non-beneficial 
research is arguably the voluntary informed consent of the human subject.1  While 
the principle of beneficence ensures that such research risks are minimised and 
appropriate in the light of the benefits to be gained from the knowledge gleaned 
from the protocol,2 and that of justice seeks to ensure that the burdens of such 
 
∗ Assistant Professor, National University of Singapore. 
 
 1. TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNALS UNDER 
CONTROL COUNCIL LAW NO. 10, VOL. 2, Nuremberg Code, Guideline 1,  at 181-82 
(Washington, D.C.: U.S. Government Printing Office, 1949), available at 
http://www.nihtraining.com/ohsrsite/guidelines/nuremberg.html [hereinafter Nuremberg 
Code]. 
 2. See, e.g., Council for International Organizations of Medical Sciences, INTERNATIONAL 
ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS, 
General Ethical Principles (CIOMS, Geneva 2002), available at  
http://www.cioms.ch/frame_guidelines_nov_2002.htm [hereinafter CIOMS Guidelines]. 
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research are fairly distributed amongst the group or community that stands to 
benefit from that research,3 ultimately it is the individual, autonomous choice to 
align oneself with the researcher’s objectives that legitimates the imposition of the 
inevitable risks associated with research participation.4  A duty to contribute to the 
biomedical research effort, while often articulated,5 has so far not passed into the 
realm of universal or general ethical acceptance. 
This autonomy paradigm for non-beneficial research raises serious ethical and 
regulatory challenges whenever children (or minors) are enrolled in non-beneficial 
research.  For empirical and legal reasons, children are considered incapable of 
giving the necessary consent to expose themselves to research risk that offers no 
direct compensating benefit.6  What is the moral or legal basis, if any at all, for 
involving children in such research?  What protections and procedures ought to be 
put in place should this practice be justified?  These issues have long been debated 
domestically, with different approaches adopted in various research jurisdictions.7 
However, their resolution takes on new significance in the light of international 
pharmaceutical development trials.  This paper considers what international 
guidelines exist and how they address the challenges posed by involving children 
in non-beneficial clinical trials, particularly in developing countries.  Part II of the 
paper describes the globalisation of pharmaceutical trials and the regulatory 
challenges vis-à-vis child subjects, while Part III reviews some domestic legal and 
ethical approaches to the issue of minimal risk.  In the light of this review, Part IV 
then evaluates the adequacy of existing international guidelines in addressing the 
needs of this vulnerable group of persons, and what needs to be done to strengthen 
them. 
 
 3. Id. 
 4. Hans Jonas, Philosophical Reflections on Human Experimentation, Daedalus 219, 235-36 
(1969). 
 5. See, e.g., R. Rhodes, Rethinking Research Ethics, 5(1) Am. J. Bioethics 7, 14-15; D. Brock, 
Ethical Issues in Exposing Children to Risks in Research, in CHILDREN AS RESEARCH 
SUBJECTS: SCIENCE, ETHICS, AND LAW 90-93 (M. Grodin & L. Glantz eds., 1994) (in 
relation to incompetent subjects). 
 6. See David N. Weisstub et al., Biomedical Experimentation with Children, in RESEARCH ON 
HUMAN SUBJECTS: ETHICS, LAW, AND SOCIAL POLICY 380, 382-84 (David N. Weisstub 
ed., 1998). 
 7. See infra Part III. 
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II. The Globalisation of Pharmaceutical Trials and Their Impact 
on Children 
A. General 
The past two decades have seen a noticeable rise in international pharmaceutical 
clinical trials in developing countries.8  The reasons for this are both scientific and 
pragmatic.  If investigational products seek to deal with diseases that are more 
common and widespread in developing countries, pharmaceutical companies are  
likely to conduct trials in countries where subjects with the relevant medical 
condition are to be found and recruited.9  Further, human subjects in developing 
countries are less likely to have been exposed to pre-existing pharmaceutical 
agents that address the condition under investigation, thus allowing better efficacy 
data to be derived.10  More significantly, there are important cost considerations in 
‘out-sourcing’ clinical investigations to countries where manpower and recruitment 
costs associated with such research are much lower.  Pharmaceutical companies 
also apparently stand to gain from greatly accelerated trial periods in countries 
where ethical and regulatory barriers are lower or non-existent as these countries 
may lack similar or basic ethical and regulatory controls as compared to the 
sponsoring jurisdiction, often because government officials and medical 
professionals lack adequate information and training in evaluating the propriety of 
these trials.  Finally, there is (at the least) a perception that recruitment in these 
developing countries, where potential subjects are far more deferential to medical 
professionals and authority figures  in general, is much easier.11 
B. Children as Therapeutic Orphans 
Clinical investigations of pharmaceutical products in children is a scientific 
necessity due to the different ranges of diseases in and physiology of children.12 
There is currently inadequate paediatric testing of pharmaceutical products, 
principally by reason of a lack of adequate economic incentives on the part of 
 
 8. Draft Report of the Joint CIOMS/WHO Working Group, DRUG DEVELOPMENT RESEARCH 
IN RESOURCE-LIMITED COUNTRIES (CIOMS, Geneva Dec. 2005) ¶ 1.2 at 7, 
http://www.cioms.ch/pv_in_rpc_final_14dec2005.pdf. 
 9. Id. ¶ 1.1 at 6. 
 10. Ruth Macklin, DOUBLE STANDARDS IN MEDICAL RESEARCH IN DEVELOPING COUNTRIES 7 
(2004). 
 11. Id. at 7-9. 
 12. Ralph E. Kauffman, Scientific Issues in Biomedical Research with Children, in CHILDREN 
AS RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW, supra note 5, at 29, 34-37. 
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pharmaceutical companies, resulting in widespread off-label prescriptions and 
interventions for children that are based on inexact extrapolations from the results 
of studies in adults.13  This presents an inherent therapeutic risk whenever 
pharmaceuticals tested in adult-only clinical trials are used in children.  As a matter 
of national health policy, some of the leading pharmaceutical development 
jurisdictions have gradually begun to work towards adopting overt regulatory or 
legislative action to encourage or mandate the inclusion of children in clinical 
trials, unless there are specific ethical or scientific reasons to exclude them.14  The 
object is to improve the information available on dosage and safety information of 
pharmaceutical products for paediatric use.  This policy is supported by major 
research groups and professional associations.15  The frontrunner of these efforts is 
the U.S. Paediatric Research Equity Act of 2003,16 which mandates such paediatric 
studies.  Apart from legislation being considered in the European Union,17 there is 
currently no similar legislation anywhere else in the world.  Notwithstanding the 
likely greater risks that would be imposed on child subjects as part of this effort, 
mandatory testing in children is seen as a better strategy than allowing current off-
label therapeutic practices, which might place even greater risks of harm on 
children, to continue.18 
C. Regulatory Challenges and the Search for Minimal Risk 
The confluence of these two trends suggests that paediatric clinical trials 
extending beyond the shores of country sponsoring the research (transnational 
trials) are likely to grow.  This has been predicted by some commentators,19 and 
indeed, domestic paediatric trials in the U.S. have increased since the regulatory 
and legislative measures were introduced by the Food and Drug Administration 
 
 13. Carol A. Tauer, Testing Drugs in Pediatric Populations: the FDA Mandate, in 7 
ACCOUNTABILITY IN RESEARCH 37, at 39-41 (1999); Patrina H Y Caldwell, Clinical 
Trials in Children, 364 LANCET 803 (2004). 
 14. Caldwell, supra note 13, at 804-05. 
 15. Id. 
 16. 21 U.S.C.S. § 301 (2006).  See Pub. L. No. 108-55, § 1, 2003 U.S.C.C.A.N. (117 Stat 
1936). (providing that “[t]his Act may be cited as the 'Pediatric Research Equity Act of 
2003.”). 
 17. Kathleen R. Gans-Brangs & Paul V. Plourde, The Evolution of Legislation to Regulate 
Pediatric Clinical Trials: Present and Continuing Challenges, ADVANCED DRUG 
DELIVERY REVIEWS 58 106-15 (2006). 
 18. Caldwell, supra note 13, at 806. 
 19. Gans-Brangs, supra note 17, at 114. 
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(FDA) and Congress respectively.20  What substantive and procedural protections 
ought to be in place before such children may be enrolled in clinical trials? 
Some international consensus has arguably emerged on the basic ethical 
requirements for paediatric clinical trials, as reflected by both domestic state 
regulations and guidelines promulgated by international public and professional 
organizations.  First and foremost, children must be protected from unwarranted 
research risk, especially since they are considered a vulnerable group of 
individuals who lack adequate autonomy to understand and evaluate research risks 
for themselves before enrolment.21  This is seen as a specification of the ethical 
principle of respect for persons or beneficence.22  What is not so clear is how this 
baseline threshold level of risk, beyond which no child should be exposed to, is to 
be defined and applied.  A distinction is often drawn between beneficial and non-
beneficial clinical research.23  In respect of the former, the level of acceptable risk 
is a function of a balancing of that risk against the prospect of direct benefits 
offered by the intervention or pharmaceutical product.24  More controversially, 
when it comes to non-beneficial clinical trials, it appears that there is widespread 
support for allowing such research that does not offer any direct benefit to the child 
subject where the risks imposed are “minimal”25 or “low”,26 although some 
jurisdictions are even prepared to go further than this if the countervailing benefits 
of the research are sufficiently important enough.27 
Second, and arguably as a corollary to this, parental “permission” to enrol the 
 
 20. A.J. FLETCHER, PRINCIPLES AND PRACTICE OF PHARMACEUTICAL MEDICINE 183  
 (Lionel D. Edwards et al. eds., 2002). 
 21. CIOMS Guidelines, supra note 2, Guideline 9. 
 22. See CIOMS Guidelines, supra note 2; Robert Veatch, Ranking, Balancing, or Simultaneity: 
Resolving the Conflict among the Belmont Principles, in BELMONT REVISITED – ETHICAL 
PRINCIPLES FOR RESEARCH WITH HUMAN SUBJECTS 196 (James F. Childress et al. eds., 
2005). 
 23. Compare United Nations Educational, Scientific and Cultural Organization [UNESCO], 
33rd Session of the General Conference of UNESCO, Oct. 19, 2005, Universal Declaration 
on Bioethics and Human Rights, ¶ 7(b), available at www.unesco.org and CIOMS 
Guidelines, supra note 2, at Guideline 8 and Guideline 9 with ICH Harmonised Tripartite 
Guideline, Clinical Investigation of Medicinal Products in the Pediatric Population; E11, ¶ 
2.6, Current Step 4 version (July 20, 2000), available at www.ich.org. 
 24. See World Medical Association, Declaration of Helsinki 2000, ¶ 16, available at 
http://www.wma.net/e/ethicsunit/helsinki.htm; CIOMS Guidelines, supra note 2, at 
Commentary to Guideline 8. 
 25. CIOMS Guidelines, supra note 2, at Guideline 9; UNESCO Declaration, supra note 23, at 
art. 7(b). 
 26. ICH Harmonised Tripartite Guideline, Guideline for Good Clinical Practice E6(R1) [10 
June 1996], para. 4.8.14,  available at http://www.ich.org/cache/compo/276-254-1.html. 
 27. 46 C.F.R. §46.407; see infra Part III.A.3. 
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child is necessary.28  “Permission”, rather than “consent”, is used to more 
accurately capture the ethical considerations involved in seeking parental approval 
before a child is enrolled in a clinical trial or research in general.  It is not a matter 
of respecting the parent’s autonomy over his individual interests, but rather, at the 
least, a respect of the parent’s prima facie authority and responsibility to determine 
the proper development and upbringing of the child.29  Furthermore, parental 
permission ensures that there is some external evaluation of a research protocol’s 
inherent risks, apart from that of the investigator and the institutional review board 
(IRB)or ethics committee.  Although the latter are better positioned to objectively 
evaluate the risks created, parents are arguably in better placed to evaluate the 
possible subjective risks (psychological or otherwise) presented in relation to the 
particular child.30 
Third, the “assent” of the child is required as well.31  “Assent” roughly refers to 
the understanding and positive agreement of the child to participate in the trial, at 
least to the extent that he or she is capable of and depends on the age, maturity and 
psychological development of the particular child.32  This essentially reflects the 
importance of respecting the developing autonomy of the child, especially if it is 
also desired to educate the child on the importance of becoming a morally 
conscious and contributing member of society.  Furthermore, respecting the dissent 
of the child ensures that undue distress or harm is avoided, particularly when the 
research is non-beneficial in nature.  Disagreement and uncertainty, however, exist 
over what age assent should be required, and if the dissent of a non-competent 
child should be respected in every situation.33 
Finally, there should be just recruitment criteria and procedures in place to 
ensure the fair spreading of the benefit and burdens of such research between 
individuals and groups who actually stand to benefit from the knowledge gained 
from such research.34  Following from this principle, it is always stipulated that it 
 
 28. See, e.g., CIOMS Guidelines, supra note 2, at Guideline 14; Cf. WMA Helsinki Declaration 
2000, supra note 24, at para. 24, which refers to the “informed” consent of a legally 
authorised representative of the incompetent subject. 
 29. See Leonard H. Glantz, Research with Children, 24 Am. J.L. & Med. 213, at 219-20 (1998). 
 30. Weisstub, supra note 6, at 392-94. 
 31. CIOMS Guidelines, supra note 2, at Guideline 14: Research involving children; Helsinki 
Declaration 2000, supra note 24, at ¶ 25. 
 32. CIOMS Guidelines, supra note 2, at Commentary on Guideline 14. 
 33. See David Wendler & Seema Shah, Should Children Decide Whether They Are Enrolled in 
Nonbeneficial Research, 3(4) Am. J. Bioethics 1 (2003). 
 34. CIOMS Guidelines, supra note 2, at Guideline 12: Equitable distribution of burdens and 
benefits in the selection of groups of subjects in research. 
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must be scientifically necessary to enrol children in the clinical trial in question 
because competent adults are unsuitable.35  Further, enrolment should not 
unnecessarily target particularly vulnerable sub-groups of children, by reason of 
economic, social inequalities or simply because they are more easily accessible by 
reason, for example, of their poor health and institutionalization.36 
In this paper, I focus on non-beneficial paediatric clinical trials, and in 
particular the application of first ethical principle of respect for persons above, 
because of the unique difficulties raised whenever incompetent and vulnerable 
subjects are sought for a trial or research that does not per se benefit them directly. 
The threshold of minimal risk essentially reflects a deontological moral threshold 
of risk, based on the respect for the individual child, beyond which it is 
impermissible to expose children to no matter what utility or beneficence the 
research offers for future child patients or society in general.37  While all the 
requirements mentioned above are undoubtedly important, additional social, 
cultural and political complications are introduced by international paediatric 
clinical trials.  The greater likelihood of exploitation of vulnerable populations 
(and parents in these communities) in developing countries and the general lack of 
adequate regulatory oversight in many developing countries,38 for example, makes 
it all the more imperative that children are protected from unnecessary and 
unethical exposure to risk in non-beneficial clinical trials. 
III. Non-Beneficial Clinical Trials Under 
 Domestic Legal and Ethical Standards 
As a starting point, it is useful to survey what limits are placed on non-
beneficial paediatric clinical trials under domestic law.  Standards and procedures 
governing research in children take varied forms.  There is often a mix of legal and 
ethical guidelines, and in federal systems, overlapping and possibly conflicting 
federal and state rules.39  What follows is a brief, selective survey of the relevant 
rules in the U.S., U.K. and Singapore that serves to highlight the main approaches 
taken and difficulties involved.40 
 
 35. Id. at Guideline 14 (research involving children). 
 36. Id. at Guideline 13 (research involving vulnerable persons). 
 37. See Veatch, supra note 22 at 196; L. Kopelman, Minimal Risk as an International Ethical 
Standard in Research, 29(3) J. Med. and Philo. 351, 352 (2004) [hereinafter Kopelman, 
Int’l Ethical Standard]. 
 38. See infra Part IV. 
 39. See Glantz, supra note 29, at 229-32. 
 40. See Kopelman, Int’l Ethical Standard, supra note 37, for a more detailed survey of the 
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A. The U.S. Federal Regulations’ Multi-layered Approach 
1. Minimal Risk Research 
The U.S. Federal Regulations, or Common Rule, represent the most multi-
layered approach to non-beneficial research involving children.  At the baseline, 
the Common Rule provides for the commonly adopted “minimal risk” standard for 
non-therapeutic paediatric research.41  Minimal risk in the Common Rule means 
that the probability and magnitude of harm or discomfort anticipated in the 
research are not greater in and of themselves than those encountered in daily life or 
during the performance of routine physical or psychological examinations or 
tests.42  The ethical justification for such “minimal risk” research is two-fold. It 
reflects a shared, communal judgment that the community benefits of such activity 
clearly outweigh exposure to a level of risk that is unavoidable and accepted as 
part of daily life.43  Therefore, it cannot be said that that child is necessarily made 
worse off by participating, if not better off.  Further, even if such research may not 
offer direct therapeutic benefit, children benefit by participation in a community 
practice in which all members have some mutual ties of responsibility to each 
other that advances their common interests, and this is also part and parcel of their 
socialisation and growth as responsible moral beings.44 
The Common Rule offers a dual test for what constitutes this “minimal” risk. 
The first limb ambiguously refers to risks encountered in daily life, which could be 
interpreted from an objective standpoint as representing some notional common 
level of unavoidable risk to which the average child in a community is exposed.  It 
would therefore reflect an absolute standard.  Alternatively, the first limb could be 
interpreted as reflecting a subjective level of risk dependent on the daily risks 
encountered by the individual paediatric subject in question.45  Fortunately, this 
alternative approach seems to be largely rejected in the U.S. on grounds that it 
could produce unjust outcomes by placing greater risk on child subjects simply 
because social, medical and economic circumstances already expose them higher 
levels of risk than more fortunate and privileged children, infringing the justice 
 
‘minimal risk’ standard. 
 41. 45 C.F.R. § 46.404 (2005).  See also 21 C.F.R. § 50.51 (2006) (the equivalent FDA 
regulation). 
 42. 45 C.F.R. § 46.303(d) (2005); 21 C.F.R. § 50.3(k) (2006). 
 43. Brock, supra note 5, at 87-88. 
 44. Id. at 89-90. 
 45. Kopelman, Int’l Ethical Standard, supra note 37, at 361-63. 
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principle outlined above.46  A subjective approach would also frustrate the 
intended purpose of expediting ethical and regulatory review on the assumption 
that the risk exposure of a given clinical trial or research protocol reflects an 
objectively minimal level of risk that obviates the necessity for closer scrutiny.47 
Unfortunately, even the former absolute everyday risks standard suffers from a 
serious shortcoming.  It assumes that common every day risks are easily 
identifiable, uniform and stable.  The U.K. Institute of Medical Ethics examined 
this approach in its 1986 report.48  After surveying a wide array of voluntarily 
accepted and daily risks for different members of the British population, it 
concluded that an everyday standard of risk (that is, risk less than that run in 
everyday life) is effectively meaningless since daily life can actually be quite 
hazardous in a variable variety of ways, dangerous sport and the like aside.49  
Comprehensive empirical data on the range of these types of risk is also lacking, 
leaving IRB members to rely on their own subjective perceptions in making risk 
assessments.50  Many of these ‘everyday’ risks are also unconsciously accepted or 
involuntarily imposed as an adjunct to activities chosen by parents for the social 
and educational developmental of the child (e.g. road travel to attend school and 
participate in sports, playing on sidewalks or playgrounds close to roads).  It does 
not follow that the same level of risk is ethically appropriate for intentionally 
chosen risk-laden activities like non-beneficial research.51 
Some commentators have defended this ‘“everyday risks’” standard on the basis 
that it ought only to focus risks that are common to us all (including driving to 
work) and is meant to be a qualitative and categorical judgment made by an IRB, 
not a quantitative test.52  The problem with the former comment is that activities 
common to us all are liable to vary, if not substantially within a community, then 
 
 46. See Loretta M. Kopelman, When is Risk Minimal Enough for Children to be Research 
Subjects, in CHILDREN AND HEALTH CARE: MORAL AND SOCIAL ISSUES 89, 95 
 (L. Kopelman & J. Moskop eds., 1989); Robert M. Nelson, Children as Research Subjects, 
in BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH 59-60 (Jeffrey P. Kahn et al. eds., 
1998). 
 47. Kopelman, Int’l Ethical Standard, supra note 37, at 363. 
 48. MEDICAL RESEARCH WITH CHILDREN: ETHICS, LAW AND PRACTICE (Richard H. Nicholson 
ed., 1986). 
 49. Id. at 84-87. 
 50. David Wendler et al., Quantifying the Federal Minimal Risk Standard: Implications for 
Pediatric Research Without a Prospect of Direct Benefit, 294(7) J. AM. MED. ASS’N. 826, 
827 (2005). 
 51. Terrence F. Ackerman, Moral Duties of Parents and Nontherapeutic Clinical Research 
Procedures Involving Children, 2(2) BIOETHICS Q. 94, 105-06 (1980). 
 52. Benjamin Freedman et al., In Loco Parentis:  Minimal Risk as an Ethical Theshold for 
Research Upon Children 23(2) HASTINGS CENTER REP. 13, 15-16 (1993). 
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most certainly between different geographical and economically under-privileged 
communities across the globe.  Further, the assumption that IRB members are 
likely to apply such a qualitative standard consistently has been proven otherwise. 
Various studies have been conducted where researchers and IRB members gave 
widely varying responses to what they considered to be minimal risks associated 
with invasive and non-invasive research procedures acceptable in research53 and 
non-beneficial research specifically.54  In short, perception of risk and its 
acceptability depends very much on the individual consulted, and it is reasonable 
to expect that IRB members who are personally involved or supportive of research 
are likely to be more optimistic about research risk that other professionals and 
laypersons.55  This does not bode well for a regulatory standard ultimately meant to 
protect the interests of children otherwise dependent on parents who may often 
have difficulty understanding the nature of research or the clinical trial in 
question.56 
This leaves us with the alternative “routine examinations” standard. Susceptible 
to the same subjective approach criticisms as the everyday risk standard, an 
objective interpretation focussing on routine examinations all healthy people might 
ordinarily encounter in the interests of both personal and public health is 
preferable.57  Examinations of the latter sort arguably approximate more closely 
with the more attenuated notions of benefit presented by clinical trials as compared 
with research that offers direct clinical benefit.58  It is also the approach commonly 
adopted by various paediatric professional boards making recommendations in 
respect of paediatric research.59  However, it must be said that this is a rather 
restrictive standard that is likely to rule out most, if not all, non-beneficial clinical 
 
 53. Jeffrey Janofsky & Barbara Starfield, Assessment of Risk in Research on Children, 98 J. 
PEDIATRICS 842 (1981). 
 54. C. Lenk et al., Non-therapeutic Research With Minors: How Do Chairpersons of German 
Research Ethics Committees Decide?, 30 J. Med. Ethics, 85 (2004). 
 55. Nicholson, supra note 48, at 104-06. 
 56. This is an extrapolation from studies on adults concerning the ‘therapeutic misconception’ 
in clinical research: see A. CATO ET AL., CLINICAL DRUG TRIALS AND TRIBULATIONS 
ch.12, pt. III (2002).  See also Michelle Obermann & Joel Frader, Dying Children and 
Medical Research: Access to Clinical Trials as Benefit and Burden  29 AM. J. L. & MED. 
301, 308-10 (2003). 
 57. Kopelman, Int’l Ethical Standard, supra note 37, at 365-67. 
 58. Cf. Wendler et al., supra note 50, at 830. 
 59. See, e.g., Samuel Gidding, et al., A Policy Regarding Research in Healthy Children, 123 J. 
PEDIATRICS 852 (1993); Ethics Advisory Committee, Royal College of Paediatrics and 
Child Health, Guidelines for the Ethical Conduct of Medical Research Involving Children, 
82 ARCHIVES DISEASE CHILDHOOD 177 (2000). 
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trials which necessarily pile on the risks of exposure to the investigational product 
over and above any routine medical procedures associated with the trial.60 
2. Minor Increase Over Minimal Risk Research 
Secondly, the Common Rule allows non-beneficial research involving a ‘minor 
increase over minimal risk’ only if, inter alia, the intervention presents experiences 
to subjects that are reasonably commensurate with those inherent in their actual or 
expected medical, dental, psychological, social or educational situations61 and is 
likely to yield generalizable knowledge about the subjects’ disorder or condition 
which is of vital importance for the understanding or amelioration of the subjects’ 
disorder or condition.62  It must be obvious that this provision compounds the 
uncertainty by adding another subjective concept of “minor” to the ambiguous 
“minimal risk” conception.  No guidance is offered as to how one resolves what 
amounts to a minor increase over the baseline “minimal risk.”63  One could infer 
that the drafters of the rule envisaged that such “minor” increases to the baseline 
threshold are justified by the fact that child subjects with the disorder or condition 
are likely by reason of their own past experiences to be better able to cope with the 
interventions proposed under the trial in question (thus minimising potential 
psychological harm) and are more likely than subjects without the relevant 
disorder or condition under investigation to potentially benefit at some future point 
should therapeutic applications for the disorder or condition materialise sooner.64 
An ethical justification offered for this standard seems to be that this higher 
level of risk exposure is nonetheless within the realm of legitimate and responsible 
parental discretion in allowing children to gain new experiences that may pose 
incrementally higher than usual “everyday” risks.65  This moves away from the 
strict best interests of the child viewed from an ideal perspective and recognises 
that parents are given leeway in exposing children to risk in familial or altruistic 
activities that have no ostensible direct and immediate benefit to them apart from 
developing their moral character.66  Critics respond that, notwithstanding this 
 
 60. Wendler et al., supra note 50, at 830. 
 61. 45 C.F.R. § 46.406(c) (2005). 
 62. 45 C.F.R. § 46.406 (2005).  See also 21 C.F.R. § 50.53 (2006). 
 63. Loretta M. Kopelman, Pediatric Research Regulations Under Legal Scrutiny: Grimes 
Narrows Their Interpretation, 30 J. L. MED. & ETHICS 38, 44 (2002). 
 64. See David Wendler et al., Non-beneficial Research with Individuals Who Cannot Consent: 
Is it Ethically Better to Enrol Healthy or Affected Individuals?, 25(4) IRB: ETHICS & 
HUMAN RESEARCH 1, 2 (2003). 
 65. Charles Weijer, The Ethical Analysis of Risk,  28 J. L. MED & ETHICS 344, 356 (2000). 
 66. Id.  See also Lanie Friedman Ross, In Defense of the Hopkins Lead Abatement Studies, 
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parental authority, the §46.406 rule as drafted will actually doubly burden sick 
children who are more likely to be exposed to increased daily risk simply because 
of their existing misfortune, and runs counter to the justice principle.  What is 
more, clinical trials may also impose uniquely greater risk on sick children for 
some types of trials, so the implicit assumption that past experience will tend to 
minimise current risks is not invariable.67  They reason that §46.406 should not 
categorically be confined to affected children; instead recruitment should first be 
determined by a requirement of scientific necessity, which incorporates due 
consideration of the particular experiences and special risks of affected children. 
That said, the responsible or scrupulous parent standard offers a more 
defensible approach to determining acceptable risk thresholds, from both a 
normative and practical perspective.68  It seeks to determine “whether the 
probability and magnitude of physical and psychological harm is no more than that 
to which it is appropriate [for a responsible parent] to intentionally expose a child 
for educational purposes in family life situations.”69  This directs the IRB to 
compare the risks presented by a clinical trial with those attendant on analogous 
decision-making scenarios that parents are presented with in disciplining and 
educating their children, thus resonating with an existing socially acceptable risk 
threshold in respect of all children in a particular community.  The responsible 
parent standard also resists a purely quantitative exercise for which empirical data 
specific to a community or country may simply be lacking, or the nature of the 
risks examined are incommensurable.70  It could actually subsume the basic 
§46.404 “minimal risks” rule since ex hypothesi, the responsible parent would not 
object to an exposure to minimal risks, provided this is measured by reference to 
analogous character-building activity that is intentionally chosen.71  However, as 
drafted, §46.406 does not explicitly mandate such an approach. 
3. The 407 Approval Process 
Finally, the Common Rule envisages exceptional situations where research 
offers a reasonable opportunity to further the understanding, prevention or 
 
 30 J. LAW MED & ETHICS 50, 54 (2002). 
 67. Wendler et al., supra, note 64, at 3. 
 68. See Lanie Friedman Ross, Do Healthy Children Deserve Greater Protection In Medical 
Research? 142 J. PEDIATRICS 108, 110 (2003); Ackerman, supra note 51, at 106-09. 
 69. Ackerman, supra note 51, at 106 (emphasis added). 
 70. Freedman et al., supra note 52, at 16-17. 
 71. Ross, supra note 68, at 110-11. 
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alleviation of a serious problem affecting the health or welfare of the children, and 
it will be conducted “in accordance with sound ethical principles”.72  This 
provision is interesting at it seems to envision exposure of child subjects to even 
greater levels of risk in the cause of the greater good of children, and perhaps even 
suggests that it might be possible to perform a utilitarian calculation to justify 
significant increases over minimal risk to further the ends stipulated.  It is 
unsettling that §46.407 does not provide any explicit ethical guidelines particularly 
on the threshold protection from research risk.  What it does seem to acknowledge 
is that we should not rule out the possibility that the importance of the research or 
harm is so great that it may occasion a community or societal reconsideration of 
the level of risk from which individual children should qualitatively be shielded. 
The protections under §46.407 essentially move from the substantive to the 
procedural.73 §46.407 provides that such research can only proceed if (a) the 
Secretary of the Department of Health and Human Services, (b) in consultation 
with a panel of experts in pertinent disciples and (c) following the opportunity for 
public review and comment, has determined that the non-beneficial research 
(notwithstanding ineligibility under §§46.404 and 46.406) can nonetheless 
ethically proceed because envisaged ethical standards may adapt in the light of 
unforeseen circumstances.  There will doubtless be detractors who argue that non-
beneficial research cannot move beyond the moral compass envisaged by either or 
both §§46.404 or 46.406.74 
On the whole, the Common Rule provisions on paediatric research reflect two 
second-order strategies75 to cope with the inherent ethical difficulties in deciding if 
and when children may be enrolled in non-beneficial clinical trials.  Although the 
more stringent rule-bound approaches under §§46.404 and 46.406 possess serious 
conceptual and practical difficulties in their formulation of risk thresholds, they 
provide greater controls over what IRBs may approve in respect of children as 
compared to §46.407.  The latter attempts to compensate for the absence of any 
explicit risk threshold by delegating the decision to a more trustworthy decision-
maker coupled with a more publicly transparent decision-making process. 
 
 72. 45 C.F.R. § 46.407 (2005).  See also 21 C.F.R. § 50.54 (2006). 
 73. See Loretta Kopelman & T. Murphy, Ethical Concerns About Federal Approval of Risky 
Pediatric Studies, 113(6) Pediatrics 1783 (2004).  See also 21 C.F.R. § 50.54 (2006). 
 74. See, e.g., Ackerman, supra note 51, at 108. 
 75. Second-order strategies are decisions about the appropriate strategy for reducing the 
problems associated with making a first-order decision.  See C. Sunstein & E. Ullmann-
Margalit, Second Order Decisions, 110 Ethics 5, 7 (1999). 
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B. The Prohibitive Approach 
In contrast, it appears that in the United Kingdom, a paediatric clinical trial 
must relate “directly to a clinical condition from which the minor suffers or is of 
such a nature that it can only be carried out in minors”,76 and “some direct benefit 
for the group of patients involved in the clinical trial is to be obtained from that 
trial.”77  The first elaborated condition reflects the requirement of scientific 
necessity, but also implicitly suggests that healthy children without any medical 
condition should not be involved in clinical research.  The latter condition is rather 
curious since it raises the immediate question of what constitutes group benefit.  If 
every child in the group must benefit, then would it not have been easier to simply 
provide for direct benefit to each trial participant?78  Perhaps what was envisaged 
was the possibility of enrolling children with a relevant medical condition in a 
randomised controlled trial (RCT).  In this scenario, while it is demonstrable that a 
majority of child subjects will randomly receive an investigational product that has 
some proven efficacy in adults, the control group will not – save perhaps for any 
demonstrable placebo effect.79  If this be the case, then the U.K. Regulations 
arguably do not provide sufficiently explicit requirements that there must still be 
some form of direct medical benefit to every individual child enrolled in the trial, 
even though on average there is a direct benefit to the group as a whole. Even if 
this were not necessary, there should still be some threshold limit of risk protecting 
children in the control group who do not receive the medicinal product under 
investigation for the period of the trial.  Some other commentators acknowledge 
the uncertainty but take a conservative interpretation of the provision to suggest 
that it precludes any non-therapeutic research – conferring no personal benefit on 
the research participant.80 
The position in Singapore is arguably much more explicit.  Although 
 
 76. The Medicines for Human Use (Clinical Trials) Regulations 2004, S.I. 1031/2004 
[hereinafter U.K. Regulations], Schedule 1, Part 4, Condition 9, available at 
www.opsi.gov.uk/si/si2004/20041031.htm. 
 77. Id. at Condition 10. 
 78. In respect of incapacitated adults, Condition 9 of Part 5 of the U.K. Regulations provides: 
“[t]here are grounds for expecting that administering the medicinal product to be tested in 
the trial will produce a benefit to the subject outweighing the risks or produce no risk at all” 
(emphasis added). 
 79. On the placebo effect in pediatric clinical trials, see Franklin Miller et al., When Do The 
Federal Regulations Allow Placebo-Controlled Trials in Children?, 142 J. PEDIAT. 102, 
105 (2003). 
 80. Lynn Hagger & Simon Woods, Children and Research: A Risk of Double Jeopardy?, in 
CHILDREN’S HEALTH AND CHILDREN’S RIGHTS 54-55 (Michael Freeman ed., 2006). 
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professional guidelines issued by the National Medical Ethics Committee similarly 
allow for non-beneficial research in children where the risks are not greater than 
those in their “everyday lives” or alternatively interventions that only constitute a 
“minor legal assault” like venepuncture.81  In contrast, the Medicines (Clinical 
Trials) Regulations 2001 provides that subjects may only be enrolled in a clinical 
trial with the appropriate consent.82  Persons who are under 21 years of age may be 
enrolled in a clinical trial in three different circumstances.  First, if the minor is 
married, then the consent of that individual shall suffice to legitimate enrolment in 
a clinical trial.83  Second, if the minor and his parent, guardian or legal 
representative (“proxy”) both give consent.84  However, in this instance, a minor 
can only jointly consent if he has “sufficient understanding” to give such consent – 
in short, if he is competent.85  Thirdly, and more pertinently, the proxy’s consent 
alone will suffice only if the minor lacks capacity to consent and “there is a 
reasonable prospect that participation in the clinical trial will directly benefit that 
person”.86  Thus, in the case of a minor who lacks the requisite decision-making 
capacity, non-therapeutic trials are simply not permissible.87  The foregoing U.K. 
and Singapore provisions arguably reflect a pre-emptive judgment that the risks 
associated with non-beneficial clinical trials, the inherent risks presented by the 
investigational product, the shortcomings of the review process, the open textured 
 
 81. National Medical Ethics Committee, Ethical Guidelines on Research Involving Human 
Subjects, in NATIONAL MEDICAL ETHICS COMMITTEE, A REVIEW OF ACTIVITIES 
(1997)(Sing.), ¶ 2.5.5.1, available at 
http://www.moh.gov.sg/corp/publications/details.do?cid=pub_reports&id=13991964. 
 82. Medicines (Clinical Trials) Regulations, r. 11 (1978 (amended 1990 and 2000)) (Sing.). 
 83. Id. at r.11(1)(a). 
 84. Id. at r.11(1)(b). 
 85. Id. at r. 11(2)(a). 
 86. Id. at r. 11(2)(b) (emphasis added). 
 87. This conclusion must be qualified by the provisions of the SINGAPORE GUIDELINE FOR 
GOOD CLINICAL PRACTICE [SGGCP], which throws a spanner [wrench] in the works. 
SINGAPORE MINISTRY OF HEALTH, SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE 
(1999).  Paragraph 4.8.14 of the SGGCP provides that non-therapeutic trials may be 
conducted in subjects with consent of a legally acceptable representative if several 
conditions are met.  These conditions mirror those in para. 4.8.14 of the ICH GCP, infra 
note 119.  Paragraph 4.8.13 defines a non-therapeutic clinical trial to mean a trial in which 
there is no anticipated direct clinical benefit to the subject.  These paragraphs are patently 
inconsistent with r. 11(2)(b) of the Medicines (Clinical Trials) Regulations discussed in the 
main text, at least in so far as paediatric clinical trials are concerned.  Paragraph 4.8.14(d) of 
the SGGCP also requires that the non-therapeutic trial not be prohibited by law, which 
presumably includes subsidiary legislation represented by r. 11(2)(b).  I surmise therefore 
that Paragraph 4.8.14 of the SGGCP is ineffectual and the full import of r. 11(2)(b) (first 
promulgated on 24 March 1978) was not appreciated when the SGGCP, based substantially 
on the ICH GCP, was introduced in 1999. 
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nature of the “minimal risk” standards available, and even possibly the disparate 
impact of parental permission to enrol on children of less-privileged families,88 are 
simply too high a price to pay without any compensating direct benefit to the 
individual child. 
It is obvious from the illustrative survey above that there is no uniform domestic 
approach to paediatric risk threshold protection.  The threshold of “minimal risk” 
is more easily stated than stipulated.  Much disagreement and uncertainty exists 
over its formulation and adequacy.  While the use of some conception of the 
“minimal” or “low” risk approach is common, this will likely produce different 
results depending on how “everyday” risks are perceived and interpreted by IRB 
members.  Contrariwise, very strict thresholds also exist that rule out non-
beneficial clinical trials altogether.  The literature on the subject, however, reveals 
a promising alternative approach based on the exercise a responsible or scrupulous 
parent standard.  Nevertheless, the U.S. Common Rule is prepared to go even 
further by providing for exceptional situations where appropriately transparent and 
public processes and more trustworthy institutions are persuaded that the research 
imposing greater than minor increases over minimal risk is ethically warranted. 
IV. The International Protection of Children in Clinical Trials 
A. Helsinki Declaration 2000 
What international principles or guidelines are in place to ensure adequate 
protection of child subjects, particularly in developing countries that often do not 
have adequate regulatory institutions or standards governing clinical research? 
There is unfortunately, but not surprisingly, no truly international treaty on the 
pharmaceutical testing.89  Paediatric clinical research was only first recognised in 
 
 88. See Ross, supra note 68, at 110 (citing William A. Silverman, The Myth of Informed 
Consent in Daily Practice and in Clinical Trials 15 J. MED ETHICS 6 (1989)); 
 S.C. Harth et al., The Psychological Profile of Parents Who Volunteer Their Children for 
Clinical Research: A Controlled Study, 18 J. MED. ETHICS 86 (1992); Cf. J.A.F. Zupancic 
et al., Determinants of Parental Authorization for Involvement of Newborn Infants in 
Clinical Trials, 99 PEDIATRICS 117 (1997). 
 89. See, e.g., Dawn Miller, Research and Accountability: The Need for Uniform Regulation of 
International Pharmaceutical Drug Testing, 13 PACE INT’L L. REV. 197, 202-11 (2001).  
The Convention on Human Rights and Biomedicine, 4 Apr. 1997, Eur. T.S. 164, only binds 
Council of Europe signatories: Benjamin Meier, Int’l Protection of Persons Undergoing 
Medical Experimentation: Protecting the Right of Informed Consent, 20 BERK. J. INT’L L. 
513, 527-29 (2002). 
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the World Medical Association’s Declaration of Helsinki 1964, which permitted 
proxy consent for all subjects who were legally incompetent in accordance with 
national legislation.90  As far as risk assessment and acceptable thresholds are 
concerned, rule 16 of Helsinki 2000 provides that “[e]very medical research 
project involving human subjects should be preceded by careful assessment of 
predictable risks and burdens in comparison with foreseeable benefits to the 
subject or to others.  This does not preclude the participation of healthy volunteers 
in medical research . . . .”91  This rule seems to allow the weighing of third party or 
community interests in determining acceptable risk-benefit ratios, suggesting that 
these may be weighed in against research risks even though there is no 
compensating direct benefit for a child subject.  Rule 18 provides that such 
research “should only be conducted if the importance of the objective outweighs 
the inherent risks and burdens to the subject.  This is especially important when the 
human subjects are healthy volunteers.”92  Finally, in addition to the recognition of 
proxy “informed consent,” rule 24 requires that research for incompetents must be 
necessary to promote the health of the population represented and cannot be 
performed on legally competent persons, while rule 25 requires the investigator to 
obtain the incompetent’s assent where this capability exists.93 
The provisions are silent on whether any risk thresholds exist for the 
recruitment of incompetent subjects or if any direct benefit is necessary.  Much 
turns on the unusual concept of “healthy volunteer” in rules 16 and 18 (which is 
undefined) since rule 18 recognises that research objectives must be weighed 
against risks and burdens to the subject even if no potential benefit to the subject 
exists.  Thus non-beneficial medical research may enrol such “healthy 
volunteers.”94  The entire context suggests two possibilities.  “Volunteers” either 
refers to subjects without a pre-existing relationship with the medical investigator 
(whatever their mental capacity), or only to subjects capable of giving free 
individual consent to participate (quite apart from whether they are adequately 
informed under rule 22).  If the former, then children may be enrolled in non-
beneficial research provided its importance outweighs the risks to the child.  The 
 
 90. World Medical Association 18th General Assembly, Declaration of Helsinki, June 1964, art. 
I.11, available at www.cirp.org/library/ethics/helsinki; Cf. Nuremberg Code, supra note 1, 
at Guideline 1. 
 91. World Medical Association 52nd General Assembly, Declaration of Helsinki, Oct. 2000, 
available at: http://www.wma.net/e/policy/b3.htm. 
 92. Id. at art. 18. 
 93. Id. at art. 24. 
 94. Id. at art. 16. 
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weight of this overriding research importance is not specified.  Otherwise, their 
incapacity precludes them from being “volunteers” in non-beneficial research. 
Helsinki 2000 is equivocal on this issue. 
B. WHO Guidelines 1995 
This latter interpretation reflects the approach taken in the World Health 
Organization’s Guidelines for Good Clinical Practice (GCP) for Trials on 
Pharmaceutical Products (“WHO Guidelines”),95 which have been of significant 
influence in the formulation of national good clinical practice guidelines.96 
Paragraph 3.3(g) stipulates that consent must always be given by the subject in a 
non-therapeutic study, while paragraph 3.3(f) provides that the inclusion of 
children in a trial may be acceptable if, inter alia, it is “permitted by local laws and 
regulations”, and “the investigator thinks that participation will promote the 
welfare and be in the interest of the subject.”97  Taken together, these provisions 
appear to preclude child enrolment in non-beneficial research, which cannot be 
said to promote the welfare of the child subject instead of merely not being 
contrary to his welfare and interests.  This prohibitive stance is also reflected in the 
recent European Directive on Good Clinical Practice in the Conduct of Clinical 
Trials (“EDGCP”).98  Article 4(e) of the EDGCP requires that a clinical trial on 
minors can only be undertaken if some direct benefit for the group of patients is 
obtained from the clinical trial.99  As discussed above in relation to the similarly 
worded U.K. provisions, this at most accepts risk exposure for the control group in 
RCT trials, and not non-beneficial trials in general.100 
 
 95. World Health Organization, Guidelines for Good Clinical Practice (GCP) for Trials on 
Pharmaceutical Products, WHO Technical Report Series No. 850, Annex 3 (1995), 
available at  http://www.vghtpe.gov.tw/~mre/goodexp/Fercap-Survey/WHO-GCP-
1995.pdf. 
 96. Draft Report of the Joint CIOMS/WHO Working Group, supra note 8 at 30, ¶ 4.5,  
 lines 29-31. 
 97. World Health Organization, supra note 95, at ¶ 3.3(f). The agreement of a legally 
acceptable representative of this effect should also be recorded by a dated signature. 
 98. Council Directive 2001/20/EC, 2001 O.J. (L121) 1 (EC), available at 
http://eudract.emea.eu.int/docs/Dir2001-20_en.pdf. This presumably overrides the 
Convention on Human Rights and Biomedicine, supra note 89, at art. 17(2), which permits 
non-beneficial research where, inter alia, it has the aim of contributing to the ultimate 
attainment of results capable of conferring benefit on the person concerned, or to other 
persons in the same category, and entails only minimal risk and minimal burden for the 
individual concerned. 
 99. Id. at L121/38. 
 100. See supra Part III.B. 
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C. CIOMS Guidelines 2002 
A more nuanced interpretation of Helsinki 2000 is embodied in the latest 
Council for International Medical Organisations’ International Ethical Guidelines 
for Biomedical Research on Human Subjects, 2002 (“CIOMS Guidelines”).101  A 
particular objective of these guidelines, developed in collaboration with the WHO, 
is to reflect the conditions and needs of “low-resource” countries in applying the 
Helsinki Declaration and developing biomedical research policies and ethical 
guidelines.102  Notwithstanding the ambiguities in Helsinki 2000, the CIOMS 
Guidelines make special provision for research involving children. Guideline 9 
specifically provides for limitations in respect of non-beneficial research involving 
incompetent individuals:  
(1)  Research interventions that do not hold out the prospect of direct 
benefit for the individual subject should be no more likely and not 
greater than risk attached to routine medical or psychological 
examinations. 
(2)  Slight or minor increases above such risk may be permitted when 
there is an overriding scientific or medical rationale for such 
increases.103 
Guideline 9 prudently adopts a routine examinations standard, obviating the 
potential for abuse inherent in an “everyday risks” standard that takes advantage of 
the heightened health and other risks disadvantaged children in the developing 
world are likely to be exposed to in their daily lives.104  There is some doubt as to 
whether this routine examinations standard is to be applied subjectively (for the 
particular individual) or objectively (those encountered by every healthy 
individual).  For reasons of fairness in the distribution of research risk mentioned 
above, the latter approach is to be preferred. 
In respect of the alternative minor increase over minimal risk standard, the 
commentary on Guideline 9 closely mirrors the stipulations of the Common Rule 
§46.406, but candidly acknowledges that there is no internationally agreed or 
precise standard of such an upper threshold of risk for non-beneficial research.105  
The suggested solution is that its meaning “is to be inferred from what various 
 
 101. CIOMS Guidelines, supra note 2. 
 102. Id. at Background. 
 103. CIOMS Guidelines, supra note 2, at Commentary on Guideline 9. 
 104. Id. at para. 2. 
 105. Id. at para. 4. 
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ethical review committees have reported as having met the standard.”106  This is 
problematic since it may devolve a large amount of discretion to a local IRB to 
determine what constitutes a “slight” or “minor” increase, which is an inherently 
subjective exercise.  Given the problems seen in variable determinations of 
minimal risk by IRB members in well established research jurisdictions,107 and the 
problems of a lack of expertise and independence in developing world regulatory 
institutions,108 this is arguably an inappropriate second-order decision making 
strategy to adopt.  Furthermore, local IRB determinations on acceptable research 
risks are rarely made publicly available,109 let alone the detailed reasons for those 
determinations.  In the absence of any substantive principle or concept grounding 
these determinations, and the general lack of comprehensive study and information 
on risk profiles,110 there is a real likelihood that such an approach would encourage 
information cascades on acceptable risk analogues for non-beneficial clinical trials, 
without adequate consideration of the relevant information, ethics and local culture 
and circumstances utilised by a “reporting” IRB in coming to its decision.111  This 
could have implications both ways, to stifle needed paediatric research or allow 
inordinate levels of risk exposure on children in developing countries. 
I suggest that a responsible or scrupulous parent standard advocated by 
Ackerman and Ross would provide an ethically sounder foundation on which 
developing world IRBs could make their deliberations.112  This would direct IRB 
members to make qualitative assessments on the socially acceptable levels of 
intentionally imposed risk that the host country is prepared to accord parents in the 
educational upbringing of their children.  In doing so, it mitigates against the 
exploitation of differing everyday risk levels across countries by focussing on 
analogous voluntary or charitable activities chosen by parents for the moral 
education of the child.  The legitimate scope of parental duty and prerogative are 
arguably questions of universal deliberation and would be a more recognizable 
 
 106. Id. at Commentary on Guideline 9, para. 4. 
 107. See supra notes 53 and 54 and accompanying text. 
 108. See infra notes 122-124 and accompanying text. 
 109. This is the situation in the U.S., where greater transparency is only likely under the §46.407 
national review process. However, such 407 reviews are exceptional, see Kopelman & 
Murphy, supra note 73, at 1787. 
 110. Wendler et al., supra note 50, at 827. 
 111. In an information cascade, people cease relying on their private information or opinions and 
decide instead on the basis of signals conveyed by others, see CASS SUNSTEIN, WHY 
SOCIETIES NEED DISSENT 55 (2003). 
 112. Supra notes 51, 68, 70 and accompanying text. 
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standard compared to appeals to essentially subjective perceptions of degrees of 
risk.  Practically speaking, there are concrete examples of appropriate parental 
interventions from which an IRB may draw inspiration or which serve as tangible 
starting points for risk investigation, such as the discipline of children, 
involvement in familial chores and charitable activities.  Furthermore, it is a 
standard that includes the consideration of subjective harms and developmental 
maturity of the particular age group in formulating acceptable risk thresholds.113  In 
this vein, a responsible parent standard, having resonance with more commonly 
understood conceptions of parental authority in a local setting, would also facilitate 
greater public understanding and feedback in the articulation and development of 
local analogues of acceptable risks.  Finally, it is to be expected that societies and 
communities may arrive at differing determinations as to the levels of risk a 
responsible parent may permit.114  This accords respect to the varying cultural, 
familial and community norms across the globe, rather than ascribe normative 
significance to the differing “everyday” risks of life in those communities over 
which parents may have little or no choice over. 
Nevertheless, it must be acknowledged that differing risk thresholds are prone 
to exploitation by investigators impeded by stricter standards in their home 
country.  Guideline 3 of the CIOMS Guidelines provides a ready solution to this: 
An external sponsoring organization and individual investigators should submit the 
research protocol for ethical and scientific review in the country of the sponsoring 
organization, and the ethical standards applied should be no less stringent than they would 
be for research carried out in that country.  The health authorities of the host country, as 
well as a national or local ethical review committee, should ensure that the proposed 
research is responsive to the health needs and priorities of the host country and meets the 
requisite ethical standards.115 
In short, there must be dual scientific and ethical review by an IRB in the host 
and sponsoring country, with each committee paying particular attention to matters 
within their competence.116  This review strategy affords a means of preventing 
potentially exploitative trials on children in host countries who are unlikely to 
 
 113. See Ackerman, supra note 51, at 107-09. 
 114. Freedman et al., supra note 52, at 17-18. 
 115. CIOMS Guidelines, supra note 2, at Guideline 3 (emphasis added).  See also  
 Freedman et al., supra note 52, at 18. 
 116. The commentary to Guideline 3 also recommends that the host country ethical review 
committee must have members or consultants who have a thorough understanding of a 
community’s customs and traditions, while Guideline 2 requires the inclusion of a variety of 
professional as well as lay persons qualified to represent cultural and moral values of the 
community. 
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benefit from them.  It could be further augmented by requiring host nation IRBs to 
provide greater public transparency and participation in evaluating appropriate risk 
thresholds given the features of the responsible parent standard discussed above. 
No doubt, this will necessarily entail greater cost and delay.  However, since the 
need to enroll children in non-beneficial trials is widely acknowledged to be 
exceptional,117 then this would be a price worth paying. 
D. The ICH Good Clinical Practice Guideline 1996 
It is unfortunate that the highly influential118 International Conference on the 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use’s (‘ICH’) Harmonized Tripartite Guideline for Good Clinical Practice 
(‘GGCP’)119 provides considerably less clear guidance on non-beneficial trials. 
Under the rubric of informed consent, paragraph 4.8.14120 of the GGCP provides 
that non-therapeutic trials may be conducted in subjects with the consent of a 
legally acceptable representative on the condition that: 
 
 
 
 
 
 
 117. See, e.g., FLETCHER et al., supra note 20, at 186.; U.S. Federal Drug Administration 
Pediatric Advisory Subcommittee, Ethics Working Group Consensus Statement (15 Nov. 
1999), ¶ 1, available at http://www.fda.gov/cder/pediatric/ethics-statement.htm. 
 118. The ICH GCP has been adopted in various non-ICH participating countries in Asia, either 
with modifications or a wholesale importation.  C.G. Fenn et al., The Contemporary 
Situation for the Conduct of Clinical Trials in Asia, 15 INT’L JOURNAL OF 
PHARMACEUTICAL MEDICINE 169, 170 (2001).  Further, many other countries in the Asia-
Pacific region are attempting to develop their regulatory systems to be compatible with ICH 
guidelines, and various regional harmonization initiatives in Asia Pacific Economic Co-
operation, Association of South East Asian Nations, Pan American Health Organisation and 
the South African Development Community participating in ICH consultations and 
consideration step-wise implementation of ICH guidelines, including the GGCP. 
 Y. Hayashi, Impact of the Int’l Conference on Harmonisation in Asia, 37 DRUG 
INFORMATION JOURNAL 129, 135-36 (2003). 
 119. ICH Harmonised Tripartite Guideline, supra note 26. 
 120. The more specific Clinical Investigation of Medicinal Products in the Pediatric Population: 
E11 does not provide any elaboration of the requirement of ‘low’ risk under 4.8.14(b), 
merely stating that paediatric participants are generally expected to benefit from the clinical 
trials.  ICH Harmonised Tripartite Guideline, Clinical Investigation of Medicinal Products 
in the Pediatric Population; E11, ¶ 2.6, (July 2000), available at 
http://www.ich.org/cache/compo/276-254-1.html [hereinafter Clinical Investigation]. 
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(1) the objectives of the trial cannot be met by means of a trial on subjects who can give 
informed consent personally, 
(2) the foreseeable risks to the subjects are low; 
(3) the negative impact on the subjects well-being is minimised and low; 
(4) the trial is not prohibited by law; 
(5) the approval of the IRB or IEC is expressly sought and written approval covers this 
aspect.121 
Paragraph 4.8.14 suffers from the usual shortcomings entailed in adopting a 
relative “low” risk threshold discussed above.  It apparently also conflates various 
distinct ethical justifications for such research in children and in doing so, 
delegates a large amount of discretion on a local IRB without any normative 
direction on how it should go about the task.  This is understandable in respect of 
ICH participating countries who have well developed ethical guidelines, regulatory 
mechanisms and expertise in place, but would not be a prudent stance in ensuring 
that adequate protections for paediatric subjects are in place for transnational 
clinical trials in developing countries.  In its report on Clinical Trials in 
Developing Countries, the former U.S. National Bioethics Advisory Committee 
(“NBAC”) observed that: 
the requirement for local review is occasionally tested and sometimes weakened when 
research is conducted in developing countries (something that can also happen within U.S. 
borders) . . . Although several developing countries have instituted national research ethics 
guidelines, and ethics review in some countries is becoming more established, many 
difficulties and challenges to local review remain, including lack of experience with and 
expertise in ethics review principles and processes; conflict of interest among committee 
members; lack of resources for maintaining the committees; length of time it can take to 
obtain approvals . . . .122 
Further, while acknowledging that sufficient empirical evidence of the efficacy 
of local IRB review is not readily available,123 Macklin draws together sufficient 
anecdotal evidence of review lapses in clinical trials conducted in developing 
countries that suggest that we cannot assume local review processes have sufficient 
expertise and resources to ensure that ethically appropriate risk thresholds are 
adhered to, or even that an independent review will always take place in the face of 
serious conflicts of interest that exist even amongst these IRBs.124 
In the midst of a growing call for greater international harmonisation of clinical 
 
 121. Id. at ¶¶ 2.6.3-2.6.5. 
 122. National Bioethics Advisory Commission, ETHICAL AND POLICY ISSUES IN 
INTERNATIONAL RESEARCH: CLINICAL TRIALS IN DEVELOPING COUNTRIES 13 (2001), 
available at http://www.georgetown.edu/research/nrcbl/nbac/pubs.html. 
 123. Macklin, supra note 10, at 159. 
 124. Id. at 133-58. 
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practice standards, it is unfortunate that the more recent ICH Guideline on 
Paediatric Clinical Trials has not seen it as necessary to improve on the 
requirements of Paragraph 4.8.14 of the ICH GCP, particularly with respect to 
clearer substantive risk thresholds and effective review of such non-beneficial 
trials.125  This, it is submitted, is a serious lapse.  In the midst of a rise in 
transnational clinical trials, there may also be a perverse race to the bottom on the 
part of developing countries to ensure they possess more facilitative levels of 
regulatory requirements, in order to encourage more clinical trials in their countries 
and reap their direct and ancillary benefits.126  There is thus no assurance that these 
countries will also voluntarily heed the more specific CIOMS Guidelines or more 
stringent WHO Guidelines on standards of protection for children.  The success of 
the first phase of the ICH harmonization initiative, relating to technical 
requirements,127 which is strongly supported by the international pharmaceutical 
industry,128 suggests that it likely to emerge as the gold standard of not only 
technical requirements but also good clinical practices.129  Led by drug 
development jurisdictions representing 75% of the global pharmaceutical market 
and the pharmaceutical industry,130 the ICH is in the driving seat for setting the 
appropriate bar for paediatric subject protections in transnational clinical trials as 
pharmaceutical companies would have a strong economic incentive to ensure that 
trials adhere to ICH GCP rooted standards in order for product safety and efficacy 
data to be accepted in seeking product registration in ICH countries. 
For the reasons discussed above, two particular modifications to Paragraph 
 
 125. Clinical Investigation, supra note 120. 
 126. Kevin M. King, A Proposal for the Effective International Recognition of Biomedical 
Research Involving Human Subjects, 34 STAN. J. INT’L L. 163, 202 (1998). 
 127. Draft Report of the Joint CIOMS/WHO Working Group, supra note 8, at 34 ¶ 4.6. 
 128. C. Nutley argues that industry has three compelling reasons to support ICH and its 
harmonization efforts; (a) reduced development times and resources, (b) easier 
simultaneous launch of new drugs in many countries and (c) the facilitation of intra-
company globalization by the recognition of a common standard.  C. NUTLEY, THE VALUE 
AND BENEFIT OF ICH TO INDUSTRY (Jan. 2000), http://www.ich.org/cache/compo/276-254-
1.html (follow “SC Reports and Other Documents” hyperlink)(last visited Dec. 9, 2006). 
 129. The Joint CIOMS/WHO working group has agreed on the universality of the ICH principles 
relating to both scientific and ethical issues and sought to encourage and assist resource 
limited countries in their implementation by providing relevant commentaries to the 
original ICH text. See draft Report of the Joint CIOMS/WHO Working Group, supra note 
8, at 36 ¶ 5.0. 
 130. Harvey. Bale Jr., M.D., Background and History of the ICH Global Cooperation Group in 
ICH, SUMMARY REPORT OF THE 6TH ICH – NEW HORIZONS AND FUTURE CHALLENGES 
(Osaka, Japan, 13-15 Nov. 2003) at 32, available at 
http://www.ich.org/LOB/media/MEDIA1383.pdf. 
PP 8-33 TEC (AA) 12/9/2006  3:41 PM 
5 SANTA CLARA JOURNAL OF INTERNATIONAL LAW 1 (2006)  
  
32 
4.8.14 of the ICH GCP are recommended.  First, the “low” risk standard should be 
replaced by the responsible parent standard to determine acceptable risk levels for 
non-beneficial trials.  As defined, the CIOMS Guidelines’ routine examinations 
standard is likely to rule out non-beneficial clinical trials insofar as they go beyond 
routine interventions by exposing subjects to the investigational product.131  Under 
the responsible parent standard, this may be permissible even in the absence of 
direct clinical benefit, after taking into account the child subject’s prevailing health 
risks, past experiences, mental capacity, maturity and the prevailing social norms 
in his society or community.  Secondly, to counter the problem of possible 
exploitation of differing risk thresholds, dual review by sponsoring and host 
country IRBs as prescribed by CIOMS Guideline 3 should be implemented under 
Paragrah 4.8.14.132 
It should be noted that the ICH GCP only lays down the minimum standards for 
non-therapeutic paediatric trials.  Countries or regions are free to ratchet up 
protections by simply prohibiting non-beneficial trials in children, and many have 
done so.133  This works against achieving a consistent international approach to the 
problem, and may disproportionately expose children in countries with anything 
less than an absolute prohibition to the burdens imposed by such trials.  Should the 
ICH GCP instead simply follow the tack of the WHO Guidelines 1995 and the 
EDGCP?  Some commentators point out that an absolute prohibition on such 
research involvement would be to the long term detriment of children’s health and 
well-being.134  If properly applied and reviewed, the responsible parent standard in 
fact reflects a stringent objective standard pegged to the overall developmental 
welfare of child and thus should ensure their interests are not unfairly 
compromised.  It also seeks to accommodate the legitimate interests and values of 
different societies and communities, faced with their particular paediatric health 
challenges, in the search for the appropriate balance between the valid competing 
interests of encouraging clinical trials responsive to the health needs of those 
children and the respect and protection due to each individual child from research 
risks. 
 
 131. See G. Koren, Healthy Children as Subjects in Pharmaceutical Research, 24 THEORETICAL 
MED. 149, 152 (2003). 
 132. This is also the position adopted by the recent Universal Declaration on Bioethics and 
Human Rights, supra note 23, at art. 21(2). 
 133. See supra notes 76, 86 and 98. 
 134. Freedman et al., supra note 52, at 17. 
PP 8-33 TEC (AA) 12/9/2006  3:41 PM 
 The Search for Minimal Risk in International Paediatric Clinical Trials 33 
 
 
 
33
V. Conclusion 
In conclusion, the international guidelines on non-beneficial paediatric trials 
differ substantially in approach to the determination of risk thresholds.  This is 
reflective of the domestic treatment of issue, and the difficult ethical evaluations 
involved in balancing therapeutic risks inherent in untested pharmaceuticals and 
the imposition of research risks on child subjects.  Improvements to the current 
difficulties should start at the ICH GCP forum given the influence this conference 
has on the general move towards greater international harmonisation on drug 
development regulations.  Ethically appropriate risk thresholds for non-beneficial 
clinical trials should be assessed by a responsible parent standard pegged to the 
socially accepted levels of risk exposure associated with the moral and educational 
development of children.  Enhanced, dual reviews by the sponsoring and host 
country IRBs should also be required by the GCP.  This would significantly 
improve the current voluntary international framework that lacks binding 
enforcement mechanisms and perhaps also encourages more focussed empirical 
study of comparable familial risk analogues for non-beneficial paediatric clinical 
trials in order to improve the ethical assessment of research risk in such clinical 
trials. 
 
